Incyte Corp
As on 23 May, 2025 | 01:29 IST
| Open | 64.55 |
| Previous Close | 64.78 |
| Beta | 0.32 |
| High | 65.33 |
| Low | 64.05 |
| TTM EPS See historical trend | 1.84(-51.45% YoY) |
| 52 Week High | 83.92 |
| 52 Week Low | 53.58 |
| TTM PE See historical trend | 35.04(Average PE) |
| Mkt. Cap ($ Billion) | 14.48 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 64.31 |
| 10 | 62.61 |
| 20 | 61.68 |
| 50 | 61.15 |
| 100 | 66.36 |
| 200 | 67.23 |
Returns
| 1 Week | 2.78% | |
| 1 Month | 12.33% | |
| 3 Months | -10.56% | |
| YTD | -6.50% | |
| 1 Year | 10.76% | |
| 3 Years | -13.91% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 732.30 | -0.25 | 695.17 | 123.70 | 5.92 | 0.96 | 746.56/0.00 | -13.33 | Neutral |
| Merck | 83.22 | -1.01 | 211.17 | 26.93 | 3.09 | 2.53 | 85.48/0.00 | 0.24 | Bearish |
| Amgen | 313.69 | 0.42 | 163.24 | 17.49 | 17.42 | 3.52 | 329.72/215.32 | -1.81 | Bearish |
| Gilead Sciences | 112.54 | -1.21 | 140.23 | 16.10 | 6.99 | 3.89 | 115.22/0.00 | 8.07 | Bearish |
| Pfizer | 24.61 | -1.83 | 138.95 | 8.57 | 2.87 | 4.47 | 25.17/0.00 | -3.49 | Bearish |
Market news
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
About the company
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.